HIV and Hepatitis.com Coverage of the
13th Annual Conference on Retroviruses and Opportunistic Infections
February 5 - 8, 2006, Denver, CO

Pharmacology, Pharmacokinetics and Drug-drug Interactions

Combination of Boosted Tipranavir and Experimental PI TMC 125 Is Not Recommended

Acid-reducing Agents Do Not Alter the Pharmacokinetics of Lopinavir/Ritonavir Tablet

Pharmacokinetic Interaction between Atazanavir (ATV) and Lopinavir/Ritonavir (LPV/r)

Lopinavir/Ritonavir Appears to Decrease the Renal Clearance of Tenofovir in HIV Patients

Pharmacokinetics of Once-daily Fosamprenavir 1400 mg plus Atazanavir 400 mg without Ritonavir

Gene-Gene Interactions Predict Efavirenz Pharmacokinetics and Treatment Response